16 results
To provide an answer to the following questions: 1. In patients with AD, does treatment with a ChEI improve cerebral hemodynamics? 2. Is there less progression of cerebrovascular lesions on follow-up of AD patients receiving ChEI*s? 3. Does this…
The primary objective of this study is to investigate whether CYP3A phenotype, as measured with midazolam clearance, correlates with cabazitaxel clearance. Our secondary objective is to investigate whether this CYP3A phenotype outperforms BSA as a…
The study will consist of three parts, part A, B and C. The main purpose of the study is to investigate to what extent VX-983 is safe and tolerated. In addition, it will be investigated how quickly and to what extent VX-983 is absorbed and…
We propose to conduct a study in healthy young and elderly subjects and patients diagnosed with mild to moderate AD, FTLD, or DLB where cholinergic and serotonergic challenges are given in a placebo-controlled, crossover fashion. Before each…
Objective: to provide an answer to the following question: in patients with AD, does treatment with a ChEI improve cerebral autoregulation?
The primary objective of this study is to determine whether the pharmacokinetics of midazolam show circadian rhythmicity.
The purpose of this investigation is: • To examine the effect of single and multiple doses of the new drug JNJ-39393406 (the study medication) on absorption, metabolism and excretion by the body after single administration of the drug midazolam.• To…
Primary aim:The primary aim of this study is to evaluate the effect of two consecutive infusions of S(+)-ketamine in patients with CRPS-I on pain relief. The design of the study is prospective, randomised, double-blind and placebo-controlled.…
To investigate the effects of galantamine on cognitive impairment and visual hallucinations in Parkinson`s disease, both therapeutic (direct effect) and preventive (protection against an acute increase of dopaminergic medication used by the patient…
• To determine the onset of action of IN MDZ as compared to IV MDZ.• To determine extend and duration of the sedative effects of 2.5 mg and 5 mg IN MDZ. • To estimate the absolute and relative bioavailability and dose proportionality of single doses…
To examine the effects of treatment with galantamine among patients with AD on the variability and stability of walking (with and without dual-task), functional mobility, standing balance, and cognitive functions (e.g. attention and executive…
The aim of the present study is to investigate the differences in patient and endoscopist satisfaction and experiences and patient*s safety with different sedation protocols.
Primary objective:The study has hierarchical co-primary objectives to demonstrate that:- Firstly: dexmedetomidine is at least as effective as sedation with midazolam and daily sedation stops, in maintaining a target depth of sedation in ventilated…
To determine the influence of OATP1B inhibition, through rifampicin exposure, on the metabolism and plasma pharmacokinetics of sorafenib and its metabolites.
We propose to conduct a study in patients with mild to moderate AD where a cholinergic challenge is given in a placebo-controlled, cross-over fashion, prior to onset of treatment with a CEI. Patients will be followed over a period of 6 months to…
To compare midazolam pharmacokinetics in morbidly obese patients before/during bariatric surgery and 0.5-2 year after surgery.